Free Trial

Contineum Therapeutics (CTNM) Competitors

Contineum Therapeutics logo
$5.77 +0.07 (+1.23%)
Closing price 04:00 PM Eastern
Extended Trading
$5.78 +0.02 (+0.26%)
As of 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CTNM vs. KMDA, PRTC, ERAS, RGNX, SNDL, AQST, CMPS, TECX, MBX, and CMPX

Should you be buying Contineum Therapeutics stock or one of its competitors? The main competitors of Contineum Therapeutics include Kamada (KMDA), PureTech Health (PRTC), Erasca (ERAS), REGENXBIO (RGNX), SNDL (SNDL), Aquestive Therapeutics (AQST), COMPASS Pathways (CMPS), Tectonic Therapeutic (TECX), MBX Biosciences (MBX), and Compass Therapeutics (CMPX). These companies are all part of the "pharmaceutical products" industry.

Contineum Therapeutics vs. Its Competitors

Contineum Therapeutics (NASDAQ:CTNM) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Kamada has higher revenue and earnings than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Contineum TherapeuticsN/AN/A-$42.26M-$1.97-2.93
Kamada$160.95M2.76$14.46M$0.2926.62

Contineum Therapeutics currently has a consensus price target of $22.50, suggesting a potential upside of 289.95%. Kamada has a consensus price target of $13.00, suggesting a potential upside of 68.39%. Given Contineum Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Contineum Therapeutics is more favorable than Kamada.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Contineum Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.17
Kamada
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

In the previous week, Contineum Therapeutics and Contineum Therapeutics both had 1 articles in the media. Kamada's average media sentiment score of 1.89 beat Contineum Therapeutics' score of 0.93 indicating that Kamada is being referred to more favorably in the news media.

Company Overall Sentiment
Contineum Therapeutics Positive
Kamada Very Positive

Contineum Therapeutics has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500. Comparatively, Kamada has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.

Kamada has a net margin of 9.60% compared to Contineum Therapeutics' net margin of 0.00%. Kamada's return on equity of 6.31% beat Contineum Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Contineum TherapeuticsN/A -24.59% -23.49%
Kamada 9.60%6.31%4.43%

20.4% of Kamada shares are held by institutional investors. 11.3% of Contineum Therapeutics shares are held by company insiders. Comparatively, 36.1% of Kamada shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Kamada beats Contineum Therapeutics on 11 of the 15 factors compared between the two stocks.

Get Contineum Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CTNM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CTNM vs. The Competition

MetricContineum TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$149.28M$3.04B$5.74B$9.51B
Dividend YieldN/A2.40%4.60%3.99%
P/E Ratio-2.9321.1828.1120.03
Price / SalesN/A337.65460.63103.88
Price / CashN/A43.2336.5559.01
Price / Book0.758.368.655.90
Net Income-$42.26M-$55.19M$3.25B$258.66M
7 Day Performance32.64%5.89%4.20%2.23%
1 Month Performance25.71%17.63%10.83%12.77%
1 Year Performance-72.59%5.10%34.67%19.36%

Contineum Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CTNM
Contineum Therapeutics
3.3655 of 5 stars
$5.77
+1.2%
$22.50
+289.9%
-73.0%$149.28MN/A-2.9331
KMDA
Kamada
4.1156 of 5 stars
$7.72
-1.1%
$13.00
+68.5%
+33.7%$445.07M$160.95M26.69360News Coverage
PRTC
PureTech Health
2.7843 of 5 stars
$18.43
-0.4%
$45.00
+144.2%
-16.2%$443.17M$4.83M0.00100Positive News
Upcoming Earnings
ERAS
Erasca
2.901 of 5 stars
$1.52
+1.3%
$4.57
+200.8%
-45.0%$429.18MN/A-2.44120
RGNX
REGENXBIO
4.1758 of 5 stars
$8.53
+4.5%
$31.63
+270.8%
-33.1%$425.76M$156.72M-2.73370News Coverage
Positive News
SNDL
SNDL
1.8885 of 5 stars
$1.64
+3.7%
$4.00
+144.2%
-30.8%$420.45M$671.81M-5.522,516News Coverage
Upcoming Earnings
Gap Up
AQST
Aquestive Therapeutics
1.7091 of 5 stars
$4.30
+2.3%
$10.14
+136.2%
+24.6%$420.06M$54.23M-7.17160
CMPS
COMPASS Pathways
1.9044 of 5 stars
$4.44
-0.4%
$17.00
+282.9%
-37.0%$418.21MN/A-2.25120Upcoming Earnings
TECX
Tectonic Therapeutic
2.6311 of 5 stars
$22.42
+2.3%
$80.33
+258.3%
+31.1%$416.62MN/A-3.05120
MBX
MBX Biosciences
2.1249 of 5 stars
$12.45
+2.1%
$37.57
+201.8%
N/A$416.30MN/A0.0036News Coverage
CMPX
Compass Therapeutics
3.025 of 5 stars
$3.06
+1.8%
$12.67
+314.6%
+230.9%$414.85M$850K-7.5720Positive News

Related Companies and Tools


This page (NASDAQ:CTNM) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners